Christopher Patusky - 24 Jul 2025 Form 4 Insider Report for UNITED THERAPEUTICS Corp (UTHR)

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
28 Jul 2025, 06:27:00 UTC
Prior SEC filing
20 Mar 2025
Next SEC filing
16 Dec 2025
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ John S. Hess, Jr. under Power of Attorney
Filing notes and source

Key filing fact

Christopher Patusky filed Form 4 for UNITED THERAPEUTICS Corp (UTHR) on 28 Jul 2025.

Key facts

  • This page summarizes Christopher Patusky's Form 4 filing for UNITED THERAPEUTICS Corp (UTHR).
  • 4 reported transactions and 3 derivative rows are listed below.
  • Accepted by SEC: 28 Jul 2025, 06:27.

Change

  • Previous filing in this sequence was filed on 20 Mar 2025.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001231427 Primary reporting owner

PATUSKY CHRISTOPHER

Relationship
Director
Address
C/O UNITED THERAPEUTICS CORPORATION, 1000 SPRING STREET, SILVER SPRING
Signature
/s/ John S. Hess, Jr. under Power of Attorney
Signature date
25 Jul 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

UTHR transaction

Common Stock

Options Exercise

Transaction value
$0
Shares
+590
Change %
+66%
Price
$0.000000
Shares after
1,490
Date
25 Jul 2025
Ownership
Direct
Footnotes
F1
UTHR holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
1,100
Date
24 Jul 2025
Ownership
by Trust

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

UTHR transaction Derivative

Restricted Stock Unit

Options Exercise

Transaction value
$0
Shares
-590
Change %
-100%
Price
$0.000000
Shares after
0
Date
25 Jul 2025
Ownership
Direct
Underlying class
Common Stock
Underlying amount
590
Exercise price
$0.000000
Footnotes
F1, F2, F3
UTHR transaction Derivative

Stock Options

Award

Transaction value
$0
Shares
+1,830
Change %
Price
$0.000000
Shares after
1,830
Date
24 Jul 2025
Ownership
Direct
Underlying class
Common Stock
Underlying amount
1,830
Exercise price
$306.41
Footnotes
F4
UTHR transaction Derivative

Restricted Stock Unit

Award

Transaction value
$0
Shares
+650
Change %
Price
$0.000000
Shares after
650
Date
24 Jul 2025
Ownership
Direct
Underlying class
Common Stock
Underlying amount
650
Exercise price
$0.000000
Footnotes
F1, F2, F3, F4
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

Shares received upon vesting of restricted stock units on July 25, 2025. Restricted stock units converted on a one-for-one basis into shares of common stock.

Footnote F2

Each restricted stock unit represents the right to receive, following vesting, one share of United Therapeutics Corporation common stock.

Footnote F3

Not applicable as restricted stock units do not have an expiration date.

Footnote F4

Annual non-employee director award.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .